Skip to main content
Acta Pharmacologica Sinica logoLink to Acta Pharmacologica Sinica
. 2025 Apr 22;46(9):2586. doi: 10.1038/s41401-025-01559-x

Correction: Empagliflozin and liraglutide ameliorate HFpEF in mice via augmenting the Erbb4 signaling pathway

Xia-yun Ni 1,2,#, Xiao-jun Feng 1,2,#, Zhi-hua Wang 1,#, Yang Zhang 2, Peter J Little 3, Yang Cao 4, Suo-wen Xu 1,✉, Li-qin Tang 2,✉, Jian-ping Weng 1,✉
PMCID: PMC12373789  PMID: 40263569

Correction to: Acta Pharmacologica Sinica 10.1038/s41401-024-01265-0, Article published online 08 April 2024

The original affiliation for the author Xia-yun Ni, Xiao-jun Feng, Zhi-hua Wang, Suo-wen Xu and Jian-ping Weng

“Department of Endocrinology, Institute of Endocrine and Metabolic Disease, The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, Clinical Research Hospital of Chinese Academy of Sciences (Hefei), University of Science and Technology of China, Hefei 230036, China.”

Should be:

“Department of Endocrinology, Institute of Endocrine and Metabolic Disease, The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei 230036, China.”

The original article has been corrected.

Contributor Information

Suo-wen Xu, Email: sxu1984@ustc.edu.cn.

Li-qin Tang, Email: tangliqin@ustc.edu.cn.

Jian-ping Weng, Email: wengjp@ustc.edu.cn.


Articles from Acta Pharmacologica Sinica are provided here courtesy of Nature Publishing Group

RESOURCES